Broad-spectrum antibiotics are akin to nuclear bombs, obliterating every prokaryote they meet. They're effective at eliminating pathogens, sure, but they're not so great for maintaining a healthy microbiome. Ideally, we need precision antimicrobials that can target only the harmful bacteria while ignoring the other species we need in our bodies, leaving them to thrive. Enter SNIPR BIOME, a Danish company founded to do just that. Its first drug—SNIPR001—is currently in clinical trials.
admin
admin
admin